Telma MCT 50/6.25 mg Tablet

Telma MCT 50/6.25 mg Tablet

Prescription requiredRx Required

Salt Composition: Chlorthalidone (6.25mg) + Metoprolol Succinate (50mg) + Telmisartan (40mg)

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

10 Tablet

About The Product

used in the treatment of hypertension (high blood pressure). It works by relaxing the blood vessels and making the heart more efficient at pumping blood throughout the body. It also removes extra water and certain electrolytes from the body.

Description

Telma MCT 50/6.25 mg Tablet is an hypertensive medication which is used in the treatment of high blood pressure and reduce the risk of heart attacks, stroke and cardiovascular complications.

Its active ingredient is Chlorthalidone in 6.25mg composition + Metoprolol Succinate in 50mg concentration + Telmisartan in 40mg concentration. The medicine is classified as a combination of a diuretic, a beta-blocker, and an angiotensin II receptor blocker (ARB). Consult to the healthcare professional before using the medication to ensure safe and effective treatment.


Uses

Manage high blood pressure

Side Effects

Every medication has certain side effects which are manageable with various treatments. Consult the healthcare professional if any of these symptoms persist while using Telma MCT 50/6.25 mg Tablet:

  • Tiredness

  • Feeling sleepy

  • Headaches

  • Back pain

  • Difficulty in breathing

  • Stomach upset

  • Nausea

  • Muscle pain

  • Swelling of ankles and feet

  • Dizziness

  • vision change

  • palpitation

  • Fever

  • Increased potassium level

How To Use

Telma MCT 50/6.25 mg Tablet dose and duration are correctly recommended by the healthcare professional. Take the medication with food to improve the effectiveness of the treatment.

Never double up the medication on the missed one as this may cause complications during the treatment. Always follow the recommended dosage to ensure safe and effective treatment.


How It Works

Telma MCT 50/6.25 mg Tablet contains three drugs including Telmisartan that relaxes blood vessels or improving blood flow, Metoprolol reduces heart rate and decreases the workload on the heart while Chlorthalidone removes excess salt or water from the body.

Together, these medicines provide stronger and more consistent blood pressure control.

Safety Advice

Alcohol

Alcohol can worsen the side effects like low blood pressure and dizziness. Try to limit or avoid intake of alcohol while using Telma MCT 50/6.25 mg Tablet

Pregnancy

Telma MCT 50/6.25 mg Tablet is not recommended to the pregnant women as it causes serious health issues to the unborn baby.

Breast Feeding

Telma MCT 50/6.25 mg Tablet use with caution or avoid during breastfeeding as medicine passed through the breast milk which harms the baby.

Driving

Telma MCT 50/6.25 mg Tablet may cause dizziness and drowsiness in some patients. Avoid driving when any of the symptoms persist or worsen.

Kidney

Telma MCT 50/6.25 mg Tablet may cause complications in patients with kidney disease as it can affect kidney function. Patients should use this medicine with caution, and any concerns or doubts during treatment should be discussed with a healthcare professional to avoid possible complications and ensure safe use.

Liver

Telma MCT 50/6.25 mg Tablet should be used with caution in patients with liver disease, as it may affect liver function and lead to complications.

FAQs

Telma MCT 50/6.25 mg Tablet is used in patients with high blood pressure.

It helps lower blood pressure levels, thereby reducing the risk of heart disease and stroke, and supports better overall health outcomes.

References

  • Carter, B. L., Ernst, M. E., & Cohen, J. D. (2004). Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension, 43(1), 4-9.
  • Agarwal, R., Sinha, A. D., Cramer, A. E., Balmes-Fenwick, M., Dickinson, J. H., Ouyang, F., & Tu, W. (2021). Chlorthalidone for hypertension in advanced chronic kidney disease. New England Journal of Medicine, 385(27), 2507-2519.
  • Papadopoulos, D. P., & Papademetriou, V. (2009). Metoprolol succinate combination in the treatment of hypertension. Angiology, 60(5), 608-613.
  • Wikstrand, J., Andersson, B., Kendall, M. J., Stanbrook, H., & Klibaner, M. (2003). Pharmacokinetic considerations of formulation: extended-release metoprolol succinate in the treatment of heart failure. Journal of cardiovascular pharmacology, 41(2), 151-157.
  • McClellan, K. J., & Markham, A. (1998). Telmisartan. Drugs, 56(6).​

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026